Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson's Disease

Core Insights - Serina Therapeutics, Inc. has successfully closed a $5 million financing round from strategic shareholders to support the development of its lead clinical candidate SER-252 for Advanced Parkinson's disease [1][2] - The company plans to initiate a Phase 1 clinical trial for SER-252 in the fourth quarter of 2025, indicating a strong commitment to advancing its clinical pipeline [1][2] Financing Details - The financing involved the issuance of 965,250 shares of convertible preferred stock at a price of $5.18 per share, which aligns with the closing price of its common stock on April 7, 2025 [2] Product Overview - SER-252 (POZ-apomorphine) is designed to provide continuous dopaminergic stimulation (CDS), which can reduce levodopa-related motor complications in advanced Parkinson's patients [3] - The product utilizes Enable Injections' enFuse™ wearable drug delivery platform, enhancing patient comfort through easy administration via long-acting subcutaneous injection [3] Technology Platform - Serina's proprietary POZ Platform™ is based on a synthetic polymer that allows for better control in drug loading and precision in drug release rates [4] - The POZ technology aims to improve the pharmacokinetic profiles of existing drugs, potentially addressing issues like toxicity and short half-life [4] Company Background - Serina Therapeutics is a clinical-stage biotechnology company focused on developing drug candidates for neurological diseases and other indications [5] - The company is headquartered in Huntsville, Alabama, and is positioned to leverage its POZ Platform™ across various therapeutic modalities [5]